Wall Street Zen Downgrades Recursion Pharmaceuticals (NASDAQ:RXRX) to Strong Sell

Recursion Pharmaceuticals (NASDAQ:RXRX) was downgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research note issued on Saturday.

Several other research analysts have also issued reports on RXRX. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Friday, July 17th. Morgan Stanley upped their price objective on shares of Recursion Pharmaceuticals from $5.00 to $5.50 and gave the company an “equal weight” rating in a research note on Thursday, May 14th. JPMorgan Chase & Co. decreased their price objective on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating for the company in a research report on Thursday, April 30th. Finally, Needham & Company LLC reissued a “buy” rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a research note on Thursday, May 7th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $8.10.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX stock opened at $3.22 on Friday. The stock has a market cap of $1.71 billion, a price-to-earnings ratio of -3.10 and a beta of 1.03. The stock has a 50-day moving average of $3.32 and a 200-day moving average of $3.44. The company has a current ratio of 5.03, a quick ratio of 5.03 and a debt-to-equity ratio of 0.01. Recursion Pharmaceuticals has a 1-year low of $2.77 and a 1-year high of $7.18.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 50.41% and a negative net margin of 945.94%.The company had revenue of $7.67 million during the quarter, compared to analyst estimates of $10.97 million. During the same period in the prior year, the firm earned ($0.41) earnings per share. On average, equities research analysts forecast that Recursion Pharmaceuticals will post -0.9 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Blake Borgeson sold 40,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $3.96, for a total transaction of $158,400.00. Following the completion of the sale, the director owned 6,218,287 shares of the company’s stock, valued at $24,624,416.52. This trade represents a 0.64% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Najat Khan sold 23,588 shares of Recursion Pharmaceuticals stock in a transaction on Friday, June 5th. The shares were sold at an average price of $3.58, for a total transaction of $84,445.04. Following the completion of the sale, the chief executive officer owned 2,175,796 shares of the company’s stock, valued at $7,789,349.68. This represents a 1.07% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 131,937 shares of company stock worth $478,874 over the last 90 days. Company insiders own 6.65% of the company’s stock.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of large investors have recently bought and sold shares of the stock. International Assets Investment Management LLC acquired a new position in Recursion Pharmaceuticals during the 4th quarter worth approximately $31,000. Integral Investment Advisors Inc. acquired a new stake in Recursion Pharmaceuticals in the first quarter valued at approximately $39,000. Sequoia Financial Advisors LLC bought a new stake in shares of Recursion Pharmaceuticals during the fourth quarter valued at approximately $41,000. MQS Management LLC bought a new stake in shares of Recursion Pharmaceuticals during the first quarter valued at approximately $41,000. Finally, QRG Capital Management Inc. acquired a new position in shares of Recursion Pharmaceuticals during the first quarter worth approximately $47,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.